Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 4/2025

Inhalt (36 Artikel)

Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy

  • Open Access
  • Research

Natalia Szóstak, Michał Budnik, Katarzyna Tomela, Luiza Handschuh, Anna Samelak-Czajka, Bernadeta Pietrzak, Marcin Schmidt, Mariusz Kaczmarek, Łukasz Galus, Jacek Mackiewicz, Andrzej Mackiewicz, Piotr Kozlowski, Anna Philips

CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer

  • Open Access
  • Research

Päivi Sirniö, Hanna Elomaa, Anne Tuomisto, Ville K. Äijälä, Henna Karjalainen, Meeri Kastinen, Vilja V. Tapiainen, Onni Sirkiä, Maarit Ahtiainen, Olli Helminen, Erkki-Ville Wirta, Jukka Rintala, Sanna Meriläinen, Juha Saarnio, Tero Rautio, Toni T. Seppälä, Jan Böhm, Jukka-Pekka Mecklin, Markus J. Mäkinen, Juha P. Väyrynen

An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma

  • Open Access
  • Research

Liyuan Dong, Yue Ma, Guang Cao, Dongze Chen, Fengxiao Dong, Xi Jiao, Yanshuo Cao, Chang Liu, Yanni Wang, Na Zhuo, Fengyuan Wang, Yixuan Guo, Tingting Dai, Shuwei Zhang, Hao Jiao, Xingyue Zou, Jian Li, Lin Shen, Zhonghu He, Yanqiao Zhang, Zhihao Lu

Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells

  • Open Access
  • Research

Peian Cai, Haibo Sun, Tongmeng Jiang, Huawei Li, Dejing Huang, Xiaopei Hao, Wei Wang, Wenqun Xing, Guanghui Liang

Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study

  • Open Access
  • Research

Else Marit Inderberg, Nand Singh, Robert Miller, Sarah Arbe-Barnes, Henrik K. Eriksen, Berit lversen, Hedvig Vidarsdotter Juul, Jon Amund Eriksen, Karianne Risberg Handeland

Comprehensive analysis and experimental validation of disulfidptosis-associated prognostic signature and immune microenvironment characterization of gastric cancer

  • Open Access
  • Research

Huangjie Zhang, Jinguo Hu, Yuanqiang Li, Yanyang Liu, Huize Shen, Zeng Wang, Qinglin Li

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity

  • Open Access
  • Research

Chenchen Zhao, Bei Jia, Yixing Jiang, Hiroko Shike, Charyguly Annageldiyev, Joseph Cioccio, Kentaro Minagawa, Shin Mineishi, WChristopher Ehmann, Todd D. Schell, Hua Cheng, Hong Zheng

Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

  • Open Access
  • Research

Gaofei Yin, Nuan Li, Xiaohong Chen, Yang Zhang, Zhigang Huang, Wei Guo

Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data

  • Open Access
  • Research

Ana D. Ramos-Guerra, Benito Farina, Jaime Rubio Pérez, Anna Vilalta-Lacarra, Jon Zugazagoitia, Germán Peces-Barba, Luis M. Seijo, Luis Paz-Ares, Ignacio Gil-Bazo, Manuel Dómine Gómez, María J. Ledesma-Carbayo

From silent partners to potential therapeutic targets: macrophages in colorectal cancer

  • Open Access
  • Review

Hayat Khizar, Kamran Ali, Jianwei Wang

Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy

  • Open Access
  • Brief Report

Thierry Landre, Gaëtan Des Guetz

Spatial transcriptomics reveals prognostically LYZ+ fibroblasts and colocalization with FN1+ macrophages in diffuse large B-cell lymphoma

  • Open Access
  • Research

Liyuan Dai, Ning Lou, Liling Huang, Lin Li, Le Tang, Yuankai Shi, Xiaohong Han

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer

  • Open Access
  • Research

Jing Cheng, Wenwen Kang, Yueying Chen, Luyun Pan, Hedong Han, Tangfeng Lv

Revealing the role of regulatory b cells in cancer: development, function and treatment significance

  • Open Access
  • Review

Ruyu Ye, Sijia Li, Yuxiao Li, Kaixin Shi, Li Li

A tumor-binding antibody with cross-reactivity to viral antigens

  • Open Access
  • Brief Report

Michael J. Campa, Elizabeth B. Gottlin, Kevin Wiehe, Edward F. Patz Jr.

Single-cell transcriptome sequencing reveals the immune microenvironment in bronchoalveolar lavage fluid of checkpoint inhibitor-related pneumonitis

  • Open Access
  • Research

Linpeng Zheng, Fenglin Lin, Dingqin Cai, Longyao Zhang, Chenrui Yin, Yaxian Qi, Lingyou Sun, Lingchen Li, Xiewan Chen, Jianbo Zhu, Jianguo Sun

Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors

  • Open Access
  • Research

Jianming Diao, Zhigong Wei, Yiyan Pei, Junyou Ge, Yan Qing, Youneng Wei, Ye Chen, Xingchen Peng

Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors

  • Open Access
  • Research

Yuya Su, Ryo Ouchi, Pissacha Daroonpan, Miwako Hamagaki, Tohru Ikeda, Noji Rika, Naoto Nishii, Fumihiko Tsushima, Yoshihito Kano, Takahiro Asakage, Makoto Noguchi, Hiroyuki Harada, Miyuki Azuma

Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma

  • Open Access
  • Research

Zheng Yijia, Xiaoyu Li, Lina Ma, Siying Wang, Hong Du, Yun Wu, Jing Yu, Yunxia Xiang, Daiqin Xiong, Huiting Shan, Yubo Wang, Zhi Wang, Jianping Hao, Jie Wang

NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer

  • Open Access
  • Research

Yiran Yang, Leiqun Cao, Xin Xu, Dan Li, Yiran Deng, Lan Li, Bingjie Zeng, Haixia Jiang, Liang Shan, Yiwen Huang, Yunhua Xu, Lifang Ma

Development of a T cell engaging bispecific antibody targeting long non-coding RNA PVT1

  • Open Access
  • Research

Hirotaka Kato, Tomohide Tsukahara, Kenji Murata, Hiromu Nishikata, Yuka Mizue, Takashi Sasaya, Terufumi Kubo, Takayuki Kanaseki, Yoshihiko Hirohashi, Atsushi Oyagi, Tatsuo Maeda, Akihiro Miyazaki, Toshihiko Torigoe

Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response

  • Open Access
  • Research

Li Liu, Peng Wu, Bingzhi Wang, Jiyan Dong, Chaoqi Zhang, Wenchao Liu, Jianming Ying

LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8+ T cell effector function

  • Open Access
  • Research

Xiaoming Zhang, Hao Fang, Wenliang Wu, Congqing Jiang, Haizhou Wang, Yifei Shi

Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma

  • Open Access
  • Research

Hideki Kuroda, Noriyuki Kijima, Tetsuro Tachi, Shunya Ikeda, Koki Murakami, Tomoyoshi Nakagawa, Moto Yaga, Kanji Nakagawa, Reina Utsugi, Ryuichi Hirayama, Yoshiko Okita, Naoki Kagawa, Naoki Hosen, Haruhiko Kishima

Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment

  • Open Access
  • Research

Yuze Zhao, Yuguang Song, Weiping Li, Jiangping Wu, Zhengbao Zhao, Tingli Qu, Hong Xiao, Manyuan Wang, Min Zhu, Peiming Zheng, Huili Wan, Qingkun Song, Huixia Zheng, Shuo Wang

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies

  • Open Access
  • Research

Zhihao Lu, Guoping Sun, Jiancheng Li, Jun Zhao, Zishu Wang, Dong Qian, Zhe Yang, Na Li, Junsheng Wang, Shuanghu Yuan, Yusheng Wang, Suyi Li, Zhen Yang, Fengming Ran, Yinghua Ji, Shaojin Zhu, Yanqiao Zhang, Chen Wang, Lixin Wan, Rongrong Zheng, Wenjie Deng, Fengzhuo Cheng, Lin Shen

PRMT5 highly expressed on CD16 + CD56- natural killer cells is correlated with NK cells exhaustion in colorectal cancer mesenchyme

  • Open Access
  • Research

Zunzhen Nie, Juanjuan Chang, Zhiqin Yang, Kaixuan Zeng, Yuangang Liu, Qian Tu, Chao Wang, Qingguo Yan, Hai Shi, Ying Guo

Microbial dysbiosis with tryptophan metabolites alteration in lower respiratory tract is associated with clinical responses to anti-PD-1 immunotherapy in advanced non-small cell lung cancer

  • Open Access
  • Research

Xiang-xiang Chen, Qing Ju, Dan Qiu, Ying Zhou, Yuan Wang, Xin-xin Zhang, Jing-geng Li, Min Wang, Ning Chang, Xiang-rui Xu, Yi-bo Zhang, Tong Zhao, Ke Wang, Yong Zhang, Jian Zhang

ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma

  • Open Access
  • Brief Report

Chloé Wirbel, Simon Durand, Félix Boivin, Maud Plaschka, Valentin Benboubker, Maxime Grimont, Laetitia Barbollat-Boutrand, Garance Tondeur, Brigitte Balme, Olivier Harou, Anaïs Eberhardt, Stéphane Dalle, Jonathan Lopez, Julie Caramel

Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab

  • Open Access
  • Research

Xuefeng Wang, Tingyi Li, Robbert J. C. Slebos, Ritu Chaudhary, Jose A. Guevara-Patino, Marcelo Bonomi, Nabil F. Saba, Christine H. Chung

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer

  • Open Access
  • Research

Manh-Cuong Vo, Van-Tan Nguyen, Van-Dinh-Huan Tran, Hyung-Joo Oh, Sung-Hoon Jung, Woo Kyun Bae, Je-Jung Lee, In-Jae Oh

Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma

  • Open Access
  • Research

Chaeyeon Kim, Mina Han, Gamin Kim, Wonrak Son, Jeongah Kim, Minchan Gil, Yong-Hee Rhee, Nam Suk Sim, Chang Gon Kim, Hye Ryun Kim

Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model

  • Open Access
  • Research

Cao Minh Nguyen, Trung T. Vu, Minh Nguyen Nguyen, Thao-Suong Tran-Nguyen, Chi Thien Huynh, Quang Thanh Ha, Hoai-Nghia Nguyen, Le Son Tran

Neu im Fachgebiet Onkologie

Nach kardiovaskulärer Erkrankung steigt das Krebsrisiko

Wer an einer kardiovaskulären Erkrankung (CVD) leidet, hat offenbar ein erhöhtes Risiko, in der Folge auch noch eine Krebsdiagnose zu erhalten. Der Zusammenhang scheint für diverse CVD und Krebsentitäten zu gelten.

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu spezifischer CAR-T-Zell-Therapie bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.